Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
United States20 participantsStarted 2021-09-01
Plain-language summary
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female 18-65 years of age.
* Candidate for a living-donor renal allograft from an HLA mismatched donor
* Subjects with chronic kidney disease stage or ESRD who are treated with either hemodialysis or peritoneal dialysis.
* First transplant.
* Use of FDA-approved methods of contraception
* Ability to understand and provide informed consent.
* Negative COVID at screening and 2 days before procedure
Exclusion Criteria:
* ABO blood group-incompatible renal allograft.
* Participant with a (non DSA) PRA \> 20% within 6 months prior to transplant
* Persistent Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia (\<100,000/mm3).
* Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (confirmed by hepatitis C virus RNA); or positivity for hepatitis B surface antigen.
* Active infection
* Left ventricular ejection fraction \< 40% as determined by TTE or clinical evidence of heart failure
* Forced expiratory volume FEV1 or DLCO \< 50% of predicted.
* Lactation or pregnancy
* History of cancer (following the American Transplant Society Guidelines)
* Underlying renal disease etiology with a high risk of disease recurrence in the transplanted kidney (such as focal segmental glomerulosclerosis).
* Prior dose-limiting radiation therapy
* Known genetic disease or family history that may result in greater sensitivity to the effects of irradiation, or a physical deformity that would preclude adequate shielding or appropriate dosing during…
What they're measuring
1
Incidence of Transient Chimerism
Timeframe: 36 months after immunosuppression withdrawal
2
Incidence of Chimerism Transition Syndrome
Timeframe: 36 months after immunosuppression withdrawal
3
Incidence of tolerance induction
Timeframe: 36 months after immunosuppression withdrawal